Friday, October 29, 2021
8:30 a.m. – 1:30 p.m.
As part of the recent formation of the NeuroGenomics and Informatics Center, and our move to a new office and lab space at 4444 Forest Park Ave, we are organizing an inaugural symposium.
The goal of this symposium is to bring together researchers who are interested in the genomics of neurodegenerative diseases so that they can share their work and recent accomplishments. This symposium will promote the NGI Center’s mission to learn about how genetics and genomics is becoming instrumental to the generation of novel molecular prediction models, identification of druggable targets, and for precision medicine in general through multi-disciplinary and collaborative approaches. This will be an opportunity to learn more about neurodegenerative disease, and what is happening at the basic science level through clinical practice in both academic and industry settings.
You can learn more about our speakers here.
This symposium is open to anyone, but if you would like to learn more about becoming an affiliated member of the NGI, click here.
| Time (CDT) | ||
|---|---|---|
| 8:30-8:45 |  | Carlos Cruchaga Director, NeuroGenomics and Informatics Center Welcome (bio) |
| 8:45-9:45 |  | Andrew Singleton Director of the NIH Center for Alzheimer’s and Related Dementias “A Global and Collaborative Approach to Neurodegeneration Research” (bio)) |
| 9:45-10:45 |  | Rosa Rademakers VIB science Director and Group Leader VIB University of Antwerp, Belgium “From Genes to Pathomechanisms: Frontotemporal Dementia Unveiled” (bio) |
| 10:45-11:00 | Break | |
| 11:00-12:00 |  | Alison Goate Director of the Ronald M Loeb Center for Alzheimer’s Disease “Genetics Implicates Efferocytosis in Alzheimer’s Disease Risk” (bio) |
| 12:00-1:00 |  | Ellen Tsai Associate Director Biogen Translational Genome Sciences group “Leveraging Human Genetics to Identify Targets and Support Therapies for Neurological Diseases” (bio) |
| 1:00-1:30 | Closing remarks |